Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Sernova Corp. (SEOVF : OTC)
 
 • Company Description   
Sernova Corp. is a regenerative medicine company. It is engaged in developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. The company's implantable medical device for therapeutic cells consists of Cell Pouch(TM). Sernova Corp. is headquartered in London, Canada.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.20 Daily Weekly Monthly
20 Day Moving Average: 100,929 shares
Shares Outstanding: 262.63 (millions)
Market Capitalization: $315.16 (millions)
Beta: 1.17
52 Week High: $1.76
52 Week Low: $0.92
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 4.35% 13.88%
12 Week 8.11% 13.82%
Year To Date -17.24% -3.53%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
700 COLLIP CIRCLE SUITE 114
-
LONDON,A6 N6G 4X8
CAN
ph: 877-299-4603
fax: 519-858-5099
info@sernova.com http://www.sernova.com
 
 • General Corporate Information   
Officers
Philip M. Toleikis - President and Chief Executive Officer
Frank Holler - Chairman
David Swetlow - Chief Financial Officer
James Parsons - Director
Jeffrey Bacha - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED INSTRUMENTS
Sector: Medical
CUSIP: 81732W104
SIC: 2834
Fiscal Year
Fiscal Year End: October
Last Reported Quarter: 01/01/22
Next Expected EPS Date: 06/24/22
Share - Related Items
Shares Outstanding: 262.63
Most Recent Split Date: (:1)
Beta: 1.17
Market Capitalization: $315.16 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 06/24/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 14.04
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -100.00%
vs. Previous Quarter: -100.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
04/30/22 - -
01/31/22 - -36.34
10/31/21 - -27.92
ROA
04/30/22 - -
01/31/22 - -34.73
10/31/21 - -26.58
Current Ratio
04/30/22 - -
01/31/22 - -
10/31/21 - 19.19
Quick Ratio
04/30/22 - -
01/31/22 - -
10/31/21 - 19.19
Operating Margin
04/30/22 - -
01/31/22 - -
10/31/21 - -
Net Margin
04/30/22 - -
01/31/22 - -
10/31/21 - -
Pre-Tax Margin
04/30/22 - -
01/31/22 - -
10/31/21 - -
Book Value
04/30/22 - -
01/31/22 - -
10/31/21 - 0.09
Inventory Turnover
04/30/22 - -
01/31/22 - -
10/31/21 - -
Debt-to-Equity
04/30/22 - -
01/31/22 - -
10/31/21 - 0.01
Debt-to-Capital
04/30/22 - -
01/31/22 - -
10/31/21 - 0.97
 

Powered by Zacks Investment Research ©